Moderna's $305 Price Target Rests on a Melanoma Filing That Hasn't Been Submitted Yet
Published on 11/09/2026 at 21:41 | Editorial boerse-global.de
Two of Wall Street's most closely watched research desks raised their price targets on Moderna on the same day, and the gap between them tells you almost everything about the debate now surrounding the biotech. Piper Sandler lifted its target from $230 to $305 while keeping an "Overweight" rating. Goldman Sachs moved from $137 to $195 and stayed at "Neutral." Both firms cite growing confidence in the company's personalized cancer therapy. Neither disputes the science. They disagree on what it is worth.
At the center of that disagreement sits intismeran autogene, the individualized treatment Moderna is developing with Merck. The partners intend to file for US approval by the end of 2026, with a decision potentially arriving in 2027 if regulators give the application a clean run. Piper Sandler's base case assumes exactly that timeline.
The Data Behind the Filing
The application will lean on INTerpath-001, a Phase 3 trial that enrolled 1,137 patients with surgically resected high-risk melanoma. Participants received either intismeran plus Keytruda or the comparator treatment. Adding the personalized therapy cut the risk of recurrence or death by 42% versus Keytruda alone, and reduced the risk of distant metastasis or death by 38%.
At the 24-month mark, 82.2% of patients on the combination were relapse-free and alive, compared with 70.0% in the control arm. Longer follow-up and mature overall survival data remain outstanding, and any additional benefit on survival can only be judged once those numbers have ripened.
Goldman Sachs is watching for forthcoming kidney cancer data and possible near-term commercial opportunities in melanoma. Moderna is also testing the approach in lung, kidney and bladder cancer, which widens the opportunity set if those studies deliver.
Should investors sell immediately? Or is it worth buying Moderna?
Where the Two Analysts Part Ways
The distance between $305 and $195 is essentially a bet on execution. Piper Sandler argues that Moderna's existing vaccine business and financial reserves can carry the company through its next development phase, with oncology then supplying a second growth engine. The firm expects the balance sheet to fund a return to profitability in 2028.
Goldman's neutral stance acknowledges the improved outlook for intismeran without endorsing the full commercial vision. For investors, the practical question is how far Moderna has actually traveled from promising trial results to a broad, revenue-generating business.
Morningstar sits between the two, raising its fair value estimate from $163 to $212. The research house does not expect a profit until 2029, and only on the condition that intismeran launches successfully in melanoma and the flu vaccine achieves wider adoption.
A Balance Sheet Built for the Wait
Friday's quarterly results give the bulls something to work with. Moderna posted a net profit of $162 million in the third quarter of 2026, supported by international COVID vaccine sales and deliveries under long-term government partnerships. Cash and investments stood at $8.0 billion at the end of September, a figure that includes roughly $2.6 billion in net proceeds from convertible notes.
That cushion matters because personalized manufacturing is capital-hungry and slow. Intismeran is tailored to each patient's tumor, so commercial success will hinge on capacity, production costs and the speed of delivery. Concrete figures on throughput, per-patient costs, treatment duration and pricing would give investors real traction on the economics — and none have been disclosed yet.
A Setback That Sharpens the Focus
Moderna's norovirus program offers a reminder of how quickly clinical optimism can curdle. The interim analysis of its Phase 3 study missed the criteria for early success, and no additional cohort is planned for this season. Next steps will follow discussions with regulators. The miss raises the stakes on the more advanced programs.
A scheduled analyst event on November 12, 2026, will offer a look inside the Marlborough facility and, investors hope, more detail on manufacturing and the commercial groundwork for a launch. Priorities and development paths will be the items to watch: which programs can broaden the business, and which still need clinical proof.
Until the intismeran application is filed and reviewed, the newly raised targets are marking a path Moderna has not yet walked. The melanoma data are in hand. The manufacturing blueprint, the pricing strategy and the regulatory verdict are not.
Ad
Moderna Stock: New Analysis - 9 November
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
